Immunization of mice with tumors genetically engineered to express the B7 costimulatory molecules amphfies the antitumor inunune response mediated by CD8 + cytolytic T lymphocytes (CTL). In this report, we examined the effect ofB7-CD28 costimulation on the hierarchy of tumor epitopes. Using a combination of affinity chromatography/reversed-phase high performance liquid chromatography and CTL cloning, we show that major histocompatibility complex (MHC) class l molecules from EL4 lymphoma cells can present at least six distinct CTL epitopes presented by MHC class I molecules. Nevertheless, mice immunized with wildtype B7-negative EL4 cells develop CTL only to one immunodominant epitope. In contrast, immunization with B7-transduced EL4 cells led to not only the amplification of the CTL response to this immunodominant epitope, but also to the recognition of five otherwise silent subdominant epitopes. The adoptive transfer of a CTL clone against such a subdominant epitope cured mice bearing EL4 lymphoma growing as an ascites tumor. The fact that CTL response can be spread to normally silent epitopes as a result ofB7-CD28 costimulation suggests a novel approach to manipulate the hierarchy ofCTL epitopes and offers an opportunity to explore novel targets for T cell-mediated cancer therapy.
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F
%r an efficient T cell activation to occur, both a specific signal dehvered through the TCR by antigenic peptides-MHC and a costimulatory signal mediated by molecules of the B7 family through their ligand CD28 on T cells are required (1, 2). TCR signaling by antigen without proper costimulation may cause antigen-specific unresponsiveness (3) . By transfer of the B7-1 or B7-2 genes into mouse tumor cells, protective and sometimes curative immunity against untransfected wild-type (wt) 1 tumors has been generated in several mouse models (4) (5) (6) (7) . Immune responses amplified by B7 costimulation are mainly mediated by CD8 + CTL (8, 9) , although CD4 + T cells may also play a role in some tumor models (10, 11) .
Many potential antigenic peptides are presented by a tumor or virus, but only a few immunodominant epitopes elicit a response whereas others are silent (12, 13) . There are several possible mechanisms for this epitope hierarchy. The "hole" in the T cell repertoire may exist because of a deletion ofT cell clones in the thymic or peripheral development (13) . In addition, there is growing evidence that si~Abbreviations used in this paper: BC-SC, bulk cultured spleen cells; TAP, transporter-associated protein; wt, wild type. lent epitopes are produced with very low efficiency by normal routes of antigen processing and presentation (14) (15) (16) . Proteasome-mediated proteolysis may contribute to the selection process by either destroying the epitopes or changing the cleavage pattern (17) . The strong MHC class I-binding of most immunodominant epitopes argues that a peptide's affinity plays a role in determining its immunogenicity, although not all strongly binding peptides are immunodominant (18) (19) (20) .
The beneficial effect of B7-CD28 costimulation on the immune response to tumors could be caused by an expansion of CTL clones recognizing immunodominant tumor antigens due to the increased production of lymphokines (21) which prevents T cell anergy caused by exposure to antigen in the absence of a second signal (22, 23) . However, costimulation by B7-CD28 interaction may also make possible the recognition of additional, otherwise silent antigens by either increasing the tumor-CTL interaction or by amplifying the signaling to TCR. To be able to distinguish between these possibilities, we have employed a previously studied mouse EL4 lymphoma model (24) . The EL4 lymphoma is highly tumorigenic in syngeneic C57BL/6 mice and does not express molecules of the B7 family whereas it expresses a high level of MHC class I molecules.
It can both process and present antigens (24) . Whereas immunization of syngeneic mice with wt EL4 cells induces a weak CTL response and, at best, a partial protective immunity against challenge with wt tumor (24) (25) (26) , immunization with EL4 cells transduced with a recombinant retrovims containing mouse B7-1 cDNA (B7 + EL4) induces a strong protective immunity against wt tumor. Moreover, mice bearing a small established s.c. EL4 lymphoma can be cured by repeated injection with B7 § EL4 cells (24) .
In the current study, we first established a panel of CTL clones and long-term CTL hnes from mice immunized with B7 § EL4 cells and used them as probes to identify the CTL epitopes presented by EL4 cells. The peptides associated with MHC class I molecules of EL4 cells were isolated and subjected to HPLC fractionation. Individual peptides were then loaded into transporter-associated protein (TAP)-deficient RMA-S cells to examine the reactivity of CTL. We demonstrate that at least six distinct CTL epitopes are naturally processed and presented by the EL4 lymphoma. Using this system, we were able to trace the activation status of CTL to the corresponding epitopes in polyclonal populations, and to study the effect of B7-CD28 costimulation in the hierarchy of tumor epitopes recognized by CD8 + CTL.
Materials and Methods
Mice and Cell Lines. Female C57BL/6 mice, 4-8 wk old, were purchased from Taconic Farms, Inc. (Germantown, NY). MHC class lI-deficient female C2D mice (27) , which originated from C57BL/6 mice, were purchased from GenPharm International (Mountain View, CA). The EL4 and TIMI.4 lymphomas are ofC57BL/6 (H-2 b) origin, the P815 mastocytoma is of DBA/2 (H-2 a) origin, and the NK cell-sensitive lymphoma YAC-1 is of A/Sn origin. The B7 + EL4 line had been generated previously in our laboratory by infection of EL4 cells with pLXSN recombinant retrovirus containing murine B7-1 cDNA (24) . The mock.EL4 line was derived similarly, but infected with parental retrovirus (24) . The P815.K b and P815.D b clones are derived from P815 cells transfected with pBR327 plasmids containing H-2K b or H-2D b genomic DNA (28), respectively. RMA-S lymphoma, which is deficient in the TAP-2 peptide transporter (29) , is of C57BL/6 (H-2 b) origin. All lines were examined in a mouse antibody production test (Microbiological Associates, Inc., R_ockville, MD) and shown to be free of Mycoplasma and the following viruses: Sendai pneumonia vires, mouse hepatitis virus, pneumonia virus of mice, reovirus type 3, mouse adenovirus, Theiler's mouse encephalitis virus, ectrometia virus, minute virus of mice, polyoma virus, lactic dehydrogenase virus, epizootic diarrhea of infant mice, mouse thymic virus, Hantaan virus, K virus, mouse orphan parvo virus, mouse cytomegalovirus, and lymphocytic choriomenmgms wrus.
Generation and Assay of CTL. Methods for the immunization and assay ofEL4-reactive CTL in bulk-cultured spleen cells (BC-SC) have been described (30) . Briefly, mice were injected subcutaneously with live B7-EL4 (wt or mock transduced) or hve B7 + EL4 cells at 5 • 104/mouse or, in some experiments, at 106/ mouse. 10-14 d later, spleen cell suspensions were prepared and cocultivated for 5-7 d at 5 • 106/well with ~-irradiated (10,000 rad) B7 § EL4 cells (10S/well) in 24-well plates. BC-SC were then tested in a standard 4-h SlCr release assay as described. In six experiments, irradiated B7-EL4 cells were injected at 3-5 • 106/mouse s.c. or i.p. and the mice were boosted twice with the same number of cells at 2-wk intervals. All immunization methods gave similar results. In cell depletion assays, BC-SC from mice immunized with either B7-EL4 or B7 § EL4 were pretreated as described (30) with mAbs to murine TCR.-cx/~ (H57-597), TCR-"//~ (GL3) (PharMingen, San Diego, CA), CD4 (GK1,5), CD8 (HO2.2), or human MHC class II (L227) as a control at 20 t~g/ml plus rabbit complement before the CTL assay.
Generation of CTL Lines and Clones. To generate long-term CTL lines, '~1-5 • los/well BC-SC were restimulated every 7-14 d with 10S/well irradiated (10,000 rad) B7 + EL4 cells together with 5 • 106 irradiated (3,000 rad) syngeneic spleen cells in the presence of human recombinant IL-2 at 10 U (Cetus)/ml (1 cetus unit = 6 international units). CTL clones were obtained by bruiting dilution of CTL lines in 96-well plates.
Isolation and Purification of MHC Class 1-associated Peptides. Purified peptides were prepared from MHC proteins as described (31) , with modifications. Briefly, 20-40 g cell pellets ("-,2.7-5.5 • 10 w) of cultured B7-or B7 § EL4 cells were washed with PBS and mixed with an equal volume of solubilization buffer containing 2% NP-40, 0.8 M NaC1, 20 mM Na2EDTA, 2 mM PMSF, 100 ~M iodoacetamide, 10 I~g/ml pepstatin A, 10 ~g/ml leupeptin, and 5 ~g/ml aprotinin in PBS. The cells were gently agitated for 30 rain at 4~ nuclei removed by low-speed centrifugation at 1,500 g for 5 nfin at 4~ and the total protein concentration adjusted to 2 mg/ml. The cell lysate was clarified by centrifugation at 100,000 g for 90 rain. The H-2K b and H-2D b complexes were then purified by immunoaffinity chromatography using mAb (the Kb-specific mAb, Y-3, and the Db-specific mAb, 28-14-8S) coupled to CNBr-activated Sepharose 4B. MHC complexes were eluted with 1% TFA. Peptides were recovered by ultrafiltration using a stirred cell (Amicon Corp., Beverly, MA) with a 10,000 molecular weight cut-offand were concentrated by vacuum centrifugation. Peptides were purified on a narrow-bore HPLC system (model 130A; Apphed Biosystems, Inc., Foster City, CA) using a 100-mm column (model C18; Vydac, Hesperia, CA) at a flow rate of 100 Ixl/min at 40~ Linear acetonitrile gradients from solvent A (0.1% TFA) to solvent B (0.085% TFA in acetonitrile) were used for elution.
Peptide Sensitization of RMA-S Cells. Individual peptide fractions from B7-or B7 § EL4 cells were reconstituted in 200 Ixl PBS and t% aliquots were used for each well. For peptide sensitization, RMA-S cells were preincubated at 22~ for 48 h, labeled with 51Cr at 22~ for 2 h, incubated with eluted peptides in 96-well V-shaped plates at 37~ for 1.5 h, and the cells were subjected to a 4-h S~Cr release assay.
Animal Studies. Our method for in vivo depletion of T cell population has been described (8) . Briefly, mice were injected intraperitoneally twice with purified mAb to CD4 (GK1.5) or CD8 (2.43) at 1 rag/mouse on the day of and 14 d after tumor inoculation. Subsequently, the mice were injected on the shaved back with 5 • 104 B7 + EL4 cells. They were killed 4-5 wk later and spleen cell suspensions were prepared and subjected to FACS analysis to determine the efficiency of depletion (8) . For blocking of the B7-CD28 interaction in vivo, the mice were injected with 5 • 104 B7 + EL4 cells that had been premixed with 50 p,g of murine CTLA41g (32) . CTLA4Ig treatment was continued for a total of 2 wk by i.v. injection every other day at 50 p,g per treatment. Mice treated with an equal amount of mAb to human CD5 (clone 10.2) were used as controls. Tumor growth was monitored weekly as described (8) . For adoptive immunotherapy,
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Results
Costimulation by B7 of the Cytolytic T Cell Response to EL4
Lymphoma. We reported previously that EL4 cells transduced with a recombinant retrovirus containing murine B7-1 cDNA lost their tumorigenicity in syngeneic mice and induced a strong CTL response (24) . To determine which T cell population mediates the regression of B7 + EL4, mice were treated with anti-CD4 or anti-CD8 mAbs to deplete different T cell subpopulations, a procedure that removed >95% of the respective T cell population without affecting other cells (8, 30) . As shown in Fig. 1 A, treatment with a mAb to CD8, but not to CD4 or a control mAb, prevented the rejection of tumors induced by B7 + EL4 cells, indicating that CD8 + CTL play a key role in B7-mediated tumor rejection in this system, similar to others studied in the past (8) . Treatment with CTLA4Ig, which blocks the interaction between B7 and CD28/CTLA-4 (32), abrogated the regression of tumors induced by B7 + EL4 cells (Fig. 1 B) in syngeneic mice. Furthermore, the CTL activity of BC-SC against EL4 from mice treated with CTLA4Ig was significantly decreased (Fig. 2 A) , indicating that induction of CTL by B7 + EL4 cells was dependent on costimulation mediated by B7--CD28 interaction.
The cytolytic activity of BC-SC from B7 + EL4-immunized mice appears to be restricted by MHC class I molecules and specific for EL4 since CTL did not lyse the syngeneic lymphoma TIMI.4, the allogeneic mastocytoma P815, P815 cells transfected to express K b (P815.K b) or D b (P815.Db), or the NK-sensitive lymphoma YAC-1 (Fig. 2  B) . Experiments in which T cell subsets of BC-SC were depleted with specific mAb to TCR-ot/[3 or ~//8 or to the CD4 or CD8 markers indicated that the cytolytic activity was mediated by TCR+CD8 + o~/~ T cells (Fig. 2 C) . BC-SC generated from wt EL4-immunized mice had similar characteristics although the cytolytic activity was much lower (Fig. 2, B and C) . Taken together, the findings demonstrate that a BT-l-costimulated CD8 + CTL response can effectively destroy B7-and B7 + EL4 lymphoma cells in vitro and suggest that a similar response is involved in tumor rejection. A C57BL/6-derived anti-H-2 d CTL line was generated as described (33) and used as a control. The mice were monitored daffy for survival. To identify EL4 cell-derived antigens, peptides associated with MHC class I molecules were purified from cell lysates of in vitro-cultured EL4 cells. Peptide--MHC class I complexes were purified by affinity chromatography using specific mAbs to either K 6 or D 6 and peptides were released by acid treatment and quantitated by Edman analysis. Sequencing of the peptide pools demonstrated that the K bassociated peptides were eight amino acids long and the Db-associated peptides were nine amino acids long, sharing the consensus motit~ described (31) . Incubation of TAPdeficient R.MA-S cells at 37~ with H-2b-associated peptides prevented loss of both K b and D b from the cell surface, as detected by flow cytometry with specific mAbs (data not shown).
At least Six Distinct CTL Epitopes Are Presented by MHC
Eluted peptides were further fractionated by reversed- phase HPLC. The separation profiles of K b- (Fig. 3 A, left) and Db-derived peptides (Fig. 3 A, right) are shown. Individual peptide fractions were then loaded to sensitize RMA-S cells for CTL lysis (Fig. 3 B) . Clone 4D9 reacted Immunization with B7-EL4 Cells Cannot Induce CTL against Subdominant Tumor Antigens. The peptide-specific retention time of eluted peptides (Fig. 3 A) allowed us to explore the specificity of individual T celt clones in potyclonal CTL. BC-SC generated from mice immunized with wt EL4 or mock.EL4 (both are referred to as B7-EL4) were tested against RMA-S cells loaded with individual HPLC fractions (Fig. 4, A-C) . BC-SC from B7-EL4-immunized mice lysed wt EL4 cells (Fig. 4 A) and reacted to Kb-derived peptides in HPLC fractions 16 significantly (Fig. 4 B) but did not react with Db-derived peptides (Fig.  4 C) . These results indicate that Kb-restricted peptides in fractions 16 may contain an immunodominant peptide. The weaker CTL responses seen by immunizing mice with B7-as compared to B7 + EL4 cells (see below) is not caused by insufficient exposure to tumor antigens since two different immunization methods, multiple injections of large numbers of irradiated EL4 cells or excision of growing tumor nodules (see Materials and Methods), gave comparable results. We conclude that immunization with B7-EL4 cells induced a CTL response against an epitope presented by the H-2K b molecule, which is, therefore, referred to as immunodominant, as compared to subdominant epitopes, which were not recognized by CTL raised with the wt EL4 lymphoma.
Activation of CTL against Subdominant Tumor Antigens by Immunization with B7 + EL4
Cells. An increased activity of costimulated CTL can be caused by (a) an increased expansion of CTL clones against immunodominant antigens; (b) an activation of CTL clones reactive to subdominant epitopes; and (c) a combination of these two events. As an attempt to examine these possibilities, the CTL activity of BC-SC from mice immunized with B7 + EL4 cells was tested against RMA-S cells loaded with individual peptide fractions. The costimulated BC-SC more efficiently lysed wt EL4 cells (Fig. 4 D) and P, MA-S cells loaded with HPLC fractions 9, 10, 15, and 16 of the K b peptides (Fig. 4  E) as compared to noncostimulated BC-SC (Fig. 4 B) , indicating that the B7-CD28 interaction expanded CTL clones reactive to dominant EL4 antigens. The costimuluted BC-SC displayed a strong CTL reactivity also against D b peptides in fractions 8, 9, and 14 and a weaker CTL response against D b peptides in fractions 11, 13, and 16 (Fig.  4 F) . Since fractions 9 ofK b and 8, 9, t4, and 16 of Db contained antigenically different peptides (Fig. 3 /3 ) that did not induce any CTL activation when the mice were immunized with B7-EL4 cells, we conclude that immuni- 
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In Vivo Exposure to B7-EL4 Cells Does Not Induce Tolerance/Anergy of C T L against Subdominant Epitopes. T o ex-
B7 + EL4 Figure 6 . CTL reactivity to B7 + EL4 cells in mice exposed to B7-EL4 cells. C57BL/6 mice, in groups of 5, were injected with 5 • 104 wt EL4 cells s.c. at 3, 2, and 1 wk before or at the same time and were then challenged on the distant site with 5 X 104 B7 + EL4 cells. Tumor growth at both sites was assessed and is presented as mean minor diameters in D, C, B, and A, respectively. (E 3 2 wk after injection of B7 + EL4 cells, spleen cells were prepared and cocultured with irradiated B7 § EL4 for 5 d after which BC-SC were tested for cytolytic activity on wt EL4 cells at a ratio 80 : 1. (F) BC-SC from three mice immunized with wt EL4 at 2 wk before challenge with B7 + EL4 cells were tested for CTL activity on RMA-S cells pulsed with 1 I~1 of HPLC-fmctionated peptides. 3 d later, they were injected with 5 X 106 cells i.p. ofT cell clone C129 followed the next day by injection with 1,500 U of IL-2 i.p.; injection of IL-2 was repeated once a day for three consecutive days. Control groups were injected with IL-2 combined with a control (C57BL/6 against H-2 a) CTL line. The mice were monitored daily for survival and the experiment was terminated at day 100 after tumor inoculation.
says in Fig. 4 were all performed 2 wk after injection ofwt EL4, we conclude that the absence of a CTL response to subdominant EL4 epitopes was not caused by CTL tolerance or anergy in mice beating wt EL4 tumor.
Treatment of EL4 Ascites Tumor by Adoptive Transfer of a CTL Clone Recognizing a Subdominant Tumor Epitope.
To determine whether a CTL clone recognizing a subdominant epitope can be employed for treatment of an established EL4 tumor, we treated C57BL/6 mice that had been injected intraperitoneally with wt EL4 cells 3 d previously and had EL4 growing as an ascites tumor. Two of five mice treated with the CTL clone C129 plus IL-2 died at days 31 and 78 without visible ascites, whereas the three remaining mice were alive without sign of tumor when the experiment was terminated on day 100 (Fig. 7) . In contrast, mice treated with IL-2 combined with a control anti-H-2 d CTL line all died with ascites within 40 d of tumor cell injection.
Discussion
We have demonstrated that at least six distinct tumor peptides are processed and presented by MHC class I molecules of the EL4 lymphoma cells in such a way that they can serve as targets for recognition by CTL clones in vitro and/or in vivo. However, the majority of these CTL epitopes are silent, i.e., they fail to induce an efficient CTL response unless the B7-1 gene has been transfected into the EL4 tumor used as immunogen. They are, therefore, referred to as subdominant. Our findings thus indicate that even when a tumor expresses a multitude of potential target epitopes, and is able to present them, its immunogenicity may still be low.
One may speculate that exposure of CTL to tumor antigens presented by a B7-negative tumor, such as the EL4 lymphoma, may induce antigen-specific tolerance. In the present study, however, several lines of evidence do not support this mechanism: (a) mice bearing a large EL4 lymphoma were resistant to challenge with B7 + EL4 cells (2, and Fig. 6, A-D) ; (b) the CTL activity which could be induced by immunization with B7 + EL4 cells was not significantly affected until after 3 wk of tumor-beating status ( Fig. 6 E) ; and (c) the BC-SC from mice bearing 2-wk-old EL4 tumor could still react to several subdominant epitopes (Fig. 6 F) . Although a single injection of B7 + EL4 cells is not sufficient to induce regression of established large EL4 tumors (Fig. 6, A-D) , small tumors can be cured ifmnltiple injections of B7 + EL4 cells are initiated at an early stage of tumor growth (24) . It is noteworthy that signaling through the B7-CD28 pathway has been shown to prevent the induction of T cell anergy in vitro (22, 23) whereas it does not break already formed T cell anergy (2, 5) . Our findings thus indicate that there was no T cell tolerance/anergy at least during the first 2 wk of growth ofwt EL4 tumor.
The requirements for sensitizing a target cell for lysis by an already activated CTL clone and for activating CTL clones in a naive animal are different with presentation of much more antigenic peptides being required in the latter case (34) (35) (36) . It is thus possible that CTL clones "ignore" a peptide encoding a tumor antigen unless it is expressed at a certain level needed for activation. EL4 cells are capable of presenting subdominant epitopes (Fig. 3) but probably at low level. It is possible that one of the roles of costimulation mediated by B7-1 is to decrease such a nfinimal "threshold" requirement for antigenic peptides to activate CTL.
Our findings have several implications for the immunotherapy of cancers. Whereas a tumor can express multiple antigens recognized by CTL simultaneously, the CTL response to tumor usually is directed to one or, at best, a few antigens, a situation that may facilitate the selection of antigen-negative escape variants (12, 37, 38) . We have shown that immunization with a tumor engineered to express B7 can stimulate multiple CTL clonal expansions against an expanded array of antigens, and this should make tumor escape less likely. The generation of CTL against subdominant antigens will also offer opportunities to explore novel targets for T cell-mediated cancer therapy. 
